ML 351
- CAS No.
- 847163-28-4
- Chemical Name:
- ML 351
- Synonyms
- ML 351;ML351 NEW;ML351, 10 mM in DMSO;12/15-Lipoxygenase Inhibitor, ML351;5-(Methylamino)-2-(1-naphthalenyl)-4-oxazolecarbonitrile;5-(Methylamino)-2-(naphthalen-1-yl)oxazole-4-carbonitrile;4-Oxazolecarbonitrile, 5-(methylamino)-2-(1-naphthalenyl)-;Subarachnoid hemorrhage,inhibit,oxidative stress,ML-351,SAH,neuronal,Lipoxygenase,LOX,T1D,β-cell,ML 351,ML351,Inhibitor,non-obese diabetic
- CBNumber:
- CB83146332
- Molecular Formula:
- C15H11N3O
- Molecular Weight:
- 249.27
- MDL Number:
- MFCD04183120
- MOL File:
- 847163-28-4.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Boiling point | 507.3±60.0 °C(Predicted) |
|---|---|
| Density | 1.29±0.1 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | ≤5mg/ml in DMSO;25mg/ml in dimethyl formamide |
| form | powder |
| pka | -0.97±0.10(Predicted) |
| color | white to beige |
| InChI | 1S/C15H11N3O/c1-17-15-13(9-16)18-14(19-15)12-8-4-6-10-5-2-3-7-11(10)12/h2-8,17H,1H3 |
| InChIKey | DYXYXTDIFMDJIR-UHFFFAOYSA-N |
| SMILES | CNC1=C(C#N)N=C(O1)C2=C3C(C=CC=C3)=CC=C2 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS06 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H301 | |||||||||
| Precautionary statements | P264-P270-P301+P310-P321-P330-P405-P501 | |||||||||
| WGK Germany | WGK 3 | |||||||||
| Storage Class | 11 - Combustible Solids | |||||||||
| NFPA 704 |
|
ML 351 price More Price(39)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | SML1353 | ML351 ≥98% (HPLC) | 847163-28-4 | 5MG | $257 | 2026-04-30 | Buy |
| Sigma-Aldrich | SML1353 | ML351 ≥98% (HPLC) | 847163-28-4 | 25MG | $1020 | 2026-04-30 | Buy |
| Cayman Chemical | 16119 | ML-351 ≥98% | 847163-28-4 | 1mg | $62 | 2026-04-30 | Buy |
| Cayman Chemical | 16119 | ML-351 ≥98% | 847163-28-4 | 5mg | $213 | 2026-04-30 | Buy |
| Cayman Chemical | 16119 | ML-351 ≥98% | 847163-28-4 | 10mg | $244 | 2026-04-30 | Buy |
ML 351 Chemical Properties, Uses, Production
Description
Lipoxygenases (LOs) are non-heme iron-containing dioxygenases that catalyze the oxidation of polyunsaturated fatty acids to generate unsaturated fatty acid hydroperoxides. The immediate products of 15-LO fatty acid oxidation act as mediators in inflammation, thrombosis, and cancer. ML351 is an inhibitor of human reticulocyte 15-LO-1 (IC50 = 200 nM) with >250-fold selectivity over the related enzymes 5-LO, platelet 12-LO, 15-LO-2, ovine COX-1, and human COX-2. ML351 was shown to be protective against oxidative glutamate toxicity in mouse neuronal HT-22 cells and significantly reduced infarct size in an in vivo mouse model for ischemic stroke.
Uses
ML351 is a selective 12/15 LOX inhibitor (IC50 = 200 nM). Exhibits >250-fold selectivity over related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2. Protects against oxidative glutamate toxicity in mouse neuronal cells (HT-22) and reduces infarct size in a mouse ischemic stroke model.
Biochem/physiol Actions
ML351 is a cell penetrant, selective and highly potent human lipoxygenase-12/15 (15-Lipoxygenase-1, 12/15-LOX) inhibitor that exhibits protective effects against oxidative glutamate toxicity in mouse neuronal HT22 cells. ML351 reduces infarct size in a mouse model of ischemic stroke.
in vivo
ML351 (0-48 mg/kg; before the beginning of the STZ series and concluding 5 days after the last dose of STZ) protects against diabetes development in an STZ β-cell injury model. ML351 at 24 mg/kg (M24)+ STZ shows significantly less weight reduction compares with control group. M24 shows almost complete protection from hyperglycemia. But M48 and M0 exhibits frank hyperglycemia by day 9 of the study and significantly impaired GTTs[2].ML351 (intraperitoneal injection; 0-24 mg/kg; daily for 2 weeks) leads to improved glycemic control and significantly reduced insulitis. The reduction of β-cell death in NOD mice has been suggested to lead to reductions in insulitis, likely by mitigating the chemotactic signals released by dying β-cells. NOD + M24 animals exhibited improved glycemic control compared with NOD + M0 animals[2].
| Animal Model: | Nine-week-old male C57BL/6J mice[2] |
| Dosage: | 0 mg/kg; 24 mg/kg; 48 mg/kg; |
| Administration: | Intraperitoneal injection before the beginning of the STZ series and concluding 5 days after the last dose of STZ |
| Result: | Protected against diabetes development in an STZ β-cell injury model that mimics the inflammation seen in T1D. |
| Animal Model: | Female NOD mice develop spontaneous autoimmune diabetes between 12 and 24 weeks of age[2] |
| Dosage: | 0 mg/kg; 24 mg/kg; 48 mg/kg; |
| Administration: | Intraperitoneal injection before the beginning of the STZ series and concluding 5 days after the last dose of STZ |
| Result: | Protected Against Early Glycemic Deterioration in NOD Mice. |
storage
Store at -20°C
References
[1]. rai g, joshi n, perry s, et al. discovery of ml351, a potent and selective inhibitor of human 15-lipoxygenase-1. probe reports from the nih molecular libraries program [internet]. bethesda (md): national center for biotechnology information (us); 2010-2013 apr 15 [updated 2014 jan 13].
[2]. rai g, joshi n, jung je, et al. potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies. j med chem. 2014 may 22;57(10):4035-48.
[3]. gaffney bj. lipoxygenases: structural principles and spectroscopy. annu rev biophys biomol struct. 1996;25:431-59.
ML 351 Preparation Products And Raw materials
Raw materials
Preparation Products
ML 351 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Guangzhou Isun Pharmaceutical Co., Ltd | 020-39119399 18927568969 | isunpharm@qq.com | China | 4773 | 55 |
| Sigma-Aldrich | 021-61415566 800-8193336 | orderCN@merckgroup.com | China | 51389 | 80 |
| Shanghai Lollane Biological Technology Co.,Ltd. | 021-52996696，15000506266 15000506266 | China | 4859 | 55 | |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9799 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| Tianjin Kailiqi Biotechnology Co., Ltd. | 15076683720 | klq@cw-bio.com | China | 9780 | 55 |
| Shanghai Chaolan Chemical Technology Center | QQ：65489617 13301690235 | Sales@ATKchemical.com | China | 9711 | 58 |
| Beijing Solarbio Science & Tecnology Co., Ltd. | 17801761073 18101056239 | 3193328036@qq.com | China | 28150 | 68 |
| Angel Pharmatech, Ltd. | 17317130613 | 3358272972@qq.com | China | 3307 | 58 |
847163-28-4 (ML 351) Related Search:
1of2
